ADVERTISEMENT

Clinical Summary

Rezvilutamide improves survival in hormone-sensitive prostate cancer

Deepa Koli   |   14 November 2022

Takeaway

  • Rezvilutamide plus androgen deprivation therapy (ADT) significantly improved radiographic PFS and OS compared with bicalutamide plus ADT in patients with high-volume, metastatic, hormone-sensitive prostate cancer.

Why this matters

  • Clinical benefit and favourable safety profile support the use of rezvilutamide in combination with ADT as a standard of care for...

          

November Challenge

Ends in 9h
left
right

Topic Challenges

left
right